Textbook Of Uncommon Cancer 4Ed (Hb 2012)

The only text dealing exclusively with rare or infrequently encountered malignancies in adults and children

Now in its Fourth Edition, Textbook of Uncommon Cancer is designed to help clinicians manage the treatment of uncommon cancers, for which, in many instances, there are few established guidelines for care. No longer does each new presentation of an uncommon cancer require extended periods of research. This unique and well-established book provides balanced, authoritative, and now, wherever possible, evidence-based guidance on how to address each malignancy.

This Fourth Edition is thoroughly revised with new material as well as a new focus on evidence-based research and clinical practice throughout. Clinicians will find guidelines for dealing with management issues, gain insight into real-world clinical decision-making, and save themselves hours of painstaking research through the use of this widely acclaimed, comprehensive guide.

Features of this new edition include:

• A complete revision and update, with five new chapters and extensive revisions of more than 75 percent of the existing chapters
• Over 100 new full-color illustrations and images
• Contributions by multidisciplinary teams of medical oncologists, radiation oncologists, and other specialists, reflecting day-to-day decision-making and clinical practice

Textbook of Uncommon Cancer, Fourth Edition is an essential, self-contained guide for practicing oncologists who treat patients with rare or infrequently encountered malignancies. It is also an important resource for hematologists and other specialists who deal with malignancies in a particular organ system.

Derek Raghavan, MD, PhD, is President of the Levine CancerInstitute of the Carolinas Healthcare System in Charlotte,North Carolina. Widely published in journals and books, Dr.Raghavan has been the editor-in-chief of Textbook of UncommonCancer since its second edition.

Charles D. Blanke, MD, is Chief of the Division ofOncology at the British Columbia Cancer Agency and Professor ofMedicine at the University of British Columbia in Vancouver,Canada.

David Johnson, MD, was the longtime Director of theDivision of Hematology and Oncology at Vanderbilt University inNashville, Tennessee, and was recently appointed as Chairman ofMedicine and holds the Donald W. Seldin Distinguished Chair inInternal Medicine at the University of Texas Southwestern inDallas, Texas.

Paul L. Moots, M.D., Associate Professor of Neurology atthe Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Gregory H. Reaman, M.D., is Chair of the Children'sOncology Group at the Children’s National Medical Center inWashington, DC.

Peter G. Rose, MD, is Section Head and FellowshipDirector of Gynecologic Oncology in the Department ofObstetrics and Gynecology at the Cleveland Clinic.

Mikkael A. Sekeres, MD, is Director of the LeukemiaProgram at the Cleveland Clinic Taussig Cancer Institute.